GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (OTCPK:MAYNF) » Definitions » Beta

Mayne Pharma Group (Mayne Pharma Group) Beta : 2.51 (As of Jun. 24, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Mayne Pharma Group Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-24), Mayne Pharma Group's Beta is 2.51.


Mayne Pharma Group Beta Historical Data

The historical data trend for Mayne Pharma Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Beta Chart

Mayne Pharma Group Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.39 1.31 1.49 1.28 1.95

Mayne Pharma Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.38 1.28 1.64 1.95 2.67

Competitive Comparison of Mayne Pharma Group's Beta

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's Beta distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Beta falls into.



Mayne Pharma Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Mayne Pharma Group  (OTCPK:MAYNF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Mayne Pharma Group Beta Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Mayne Pharma Group (Mayne Pharma Group) Business Description

Traded in Other Exchanges
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.